{"id":"W2944776474","doi":"10.1158/1538-7445.sabcs18-ot3-04-02","title":"Abstract OT3-04-02: Neoadjuvant Her2-targeted therapy +/- immunotherapy with pembrolizumab (neoHIP): An open label randomized phase II trial","year":2019,"lang":"en","type":"article","venue":"Cancer Research","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of Calgary","funders":"","keywords":"Medicine; Trastuzumab; Pembrolizumab; Internal medicine; Oncology; Breast cancer; Pertuzumab; Regimen; Lapatinib; Taxane; Blockade; Metastatic breast cancer; Neoadjuvant therapy; Cancer; Immunotherapy; Receptor","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001883508,0.001613766,0.001929223,0.0002990538,0.0004709362,0.001204931,0.0008202994,0.001725032,0.007307429],"category_scores_gemma":[0.0007389164,0.0005531388,0.001455716,0.0004040541,0.001360291,0.001132351,0.0003781612,0.00274299,0.001412283],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0008694486,"about_ca_system_score_gemma":0.001371439,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0007055202,"about_ca_topic_score_gemma":0.001327398,"domain_scores_codex":[0.9994937,0.000259779,0.00003052815,0.00007971576,0.00004078637,0.00009551515],"domain_scores_gemma":[0.9994248,0.00009689537,0.0001067166,0.00005732009,0.00003854481,0.0002755986],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9618412,0.01331464,0.0009071255,0.0004103379,0.0004233833,0.00005738947,0.00003441472,0.0002377342,0.004400917,0.000133752,0.001831676,0.01640749],"study_design_scores_gemma":[0.9085146,0.08803991,0.001215326,0.00003105466,0.0002210858,0.00004461222,0.00001371016,0.0002863642,0.0004723379,0.0001458942,0.001006419,0.00000868036],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9743469,0.004408298,0.001014588,0.001636483,0.0005602905,0.01030659,0.003465606,0.0002632081,0.003998078],"genre_scores_gemma":[0.9710307,0.002575957,0.002607479,0.002602853,0.0006846578,0.01039791,0.003633509,0.00004752166,0.006419366],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.007307429,"threshold_uncertainty_score":0.02444583,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1714421442104214,"score_gpt":0.5137250226387211,"score_spread":0.3422828784282997,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}